- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.09. | SINOMAB BIO-B (03681): NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS AND REPLY FORM | 2 | HKEx | ||
| 26.09. | SINOMAB BIO-B (03681): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM | - | HKEx | ||
| 26.09. | SINOMAB BIO-B (03681): INTERIM REPORT 2025 | - | HKEx | ||
| 29.08. | SINOMAB BIO-B (03681): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2025 | - | HKEx | ||
| SINOMAB BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| 29.08. | SINOMAB BIO-B (03681): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 29.08. | SINOMAB BIO-B (03681): COMPLETION OF SUBSCRIPTIONS OF NEW SHARES UNDER GENERAL MANDATE | - | HKEx | ||
| 18.08. | SINOMAB BIO-B (03681): DATE OF BOARD MEETING | 1 | HKEx | ||
| 15.08. | SINOMAB BIO-B (03681): NEXT DAY DISCLOSURE RETURN | 3 | HKEx | ||
| 15.08. | SINOMAB BIO-B (03681): COMPLETION OF CERTAIN SUBSCRIPTIONS OF NEW SHARES UNDER GENERAL MANDATE | 1 | HKEx | ||
| 12.08. | SINOMAB BIO-B (03681): VOLUNTARY ANNOUNCEMENT COMPREHENSIVE STRATEGIC COOPERATION AGREEMENT | 1 | HKEx | ||
| 24.07. | SINOMAB BIO-B (03681): GRANT OF SHARE OPTIONS | 1 | HKEx | ||
| 22.07. | SINOMAB BIO-B (03681): SUBSCRIPTIONS OF NEW SHARES UNDER GENERAL MANDATE | 3 | HKEx | ||
| 14.07. | SINOMAB BIO-B (03681): INSIDE INFORMATION UPDATE ON THE BLA FOR SM03 (SUCIRASLIMAB) IN THE TREATMENT OF RHEUMATOID ARTHRITIS | - | HKEx | ||
| 30.06. | SINOMAB BIO-B (03681): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE ADOPTED BY THE BOARD ON 30 JUNE, 2025 | 1 | HKEx | ||
| 30.06. | SINOMAB BIO-B (03681): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 30.06. | SINOMAB BIO-B (03681): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 30 JUNE 2025, APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTORS, CHANGE IN ... | - | HKEx | ||
| 12.06. | SINOMAB BIO-B (03681): RESIGNATION OF EXECUTIVE DIRECTOR | - | HKEx | ||
| 11.06. | SINOMAB BIO-B (03681): POSTPONEMENT AND CHANGE OF VENUE OF ANNUAL GENERAL MEETING AND CHANGE OF BOOK CLOSURE PERIOD | 1 | HKEx | ||
| 09.06. | SINOMAB BIO-B (03681): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 09.06. | SINOMAB BIO-B (03681): PASSING AWAY OF AN INDEPENDENT NON-EXECUTIVE DIRECTOR AND WITHDRAWAL OF ORDINARY RESOLUTION NO. 2(D) AT THE ANNUAL GENERAL MEETING | - | HKEx |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| RECURSION PHARMACEUTICALS | 5,520 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 4,880 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome | Breakthrough Therapy designation granted based on FDA's review of available clinical evidence of safety and efficacy from all 12 patients treated in Part A of the REVEAL Phase 1/2 trials Finalized... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 44,180 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 7,460 | 0,00 % | Aktien Europa: Leichte Gewinne zum Wochenauftakt | AMSTERDAM/LONDON/PARIS/ZÜRICH (dpa-AFX) - Europas wichtigste Aktienmärkte starten am Montag zunächst freundlich in die neue Woche. Allerdings blieb die Risikobereitschaft verhalten angesichts der bleiben... ► Artikel lesen | |
| VERA THERAPEUTICS | 29,190 | +1,39 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 4, 2025, the Compensation Committee of Vera's Board of Directors granted... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 26,620 | 0,00 % | Aktien New York: Weitere Rekorde - auch dank Nvidia und Apple | NEW YORK (dpa-AFX) - Die US-Börsen haben am Montag nach einem verhaltenen Start ihre Rekordjagd fortgesetzt. Auch dank deutlicher Kursgewinne der Schwergewichte Nvidia und Apple verzeichnete der Leitindex... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 37,470 | 0,00 % | What Analysts Are Saying About Kiniksa Pharmaceuticals Stock | ||
| APOGEE THERAPEUTICS | 39,610 | 0,00 % | Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 ... | SAN FRANCISCO and BOSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for... ► Artikel lesen | |
| DISC MEDICINE | 65,86 | -1,86 % | Disc Medicine Inc: Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP) | Disc is seeking accelerated approval and priority review of its NDA submissionFDA decision to accept and file the NDA for review occurs within 60 days of submission WATERTOWN, Mass., Sept. 30,... ► Artikel lesen | |
| TANGO THERAPEUTICS | 7,690 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights | - First patient dosed in combination trial of TNG462 and Revolution Medicines RAS(ON) inhibitors - - First patient dosed in Phase 1/2 trial with TNG456, a brain-penetrant MTA-cooperative PRMT5... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 21,250 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025 | ||
| SUMMIT THERAPEUTICS | 20,870 | 0,00 % | Summit Therapeutics: HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025 | Ivonescimab in Combination with Chemotherapy in HARMONi-6, Conducted by Akeso in China, is the First Known Regimen to Achieve a Statistically Significant Clinically Meaningful Improvement in PFS... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 40,450 | 0,00 % | Mineralys auf Stifel-Forum: Strategischer Fahrplan für Blutdruckmittel Lorundrostat | ||
| PHATHOM PHARMACEUTICALS | 11,820 | 0,00 % | Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| SOLID BIOSCIENCES | 5,740 | 0,00 % | Solid Biosciences Inc.: Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CHARLESTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac... ► Artikel lesen |
SINOMAB BIOSCIENCE LTD gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SINOMAB BIOSCIENCE LTD finden Sie auf Wallstreet Online.